Equity Overview
Price & Market Data
Price: $2.81
Daily Change: -$0.13 / 4.63%
Range: $2.76 - $3.08
Market Cap: $54,756,220
Volume: 372,198
Performance Metrics
1 Week: -12.46%
1 Month: 66.27%
3 Months: 64.33%
6 Months: -50.35%
1 Year: -58.49%
YTD: -44.14%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.